Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Primary Immune Thrombocytopenic Purpura, Amegakaryocytic Aplasia, Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia), Lymphoproliferative Disorder With Secondary ITP. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinicopathologic Significance of Splenomegally in Adult Patients With Isolated Thrombocytopenia
Overview
Investigate prevalence of splenomegally in patients with isolated thrombocytopenia. Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome To explain possible causes of splenomegally in patients with isolated thrombocytopenia
Primary outcome measures
- Investigate prevalence of splenomegally in patients with isolated thrombocytopenia. Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- patients more than 18 years admitted with isolated thrombocytopenia due to primary Immune thrombocytopenic purpura amegakaryocytic aplasia Unilineage myelodysplastic syndrome ( megakaryocyte dysplasia) lymphoproliferative disorder with secondary ITP autoimmune diseases with secondary ITP Willingness to participate in the study Admitted patients or those who follow at hematology outpatients clinic
Exclusion criteria
EDTA induced pseudothrombocytopenia Platelet satellitism Drug induced thrombocytopenia Heparin induced thrombocytopenia / thrombosis syndrome post transfusion purpura Disseminated intravascular coagulopathy patients less than 18 years old patients with bicytopenia or pancytopenia Pregnancy
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Achterbergh R, Vermeer HJ, Curtis BR, Porcelijn L, Aster RH, Deenik W, Daemen-Gubbels C. Thrombocytopenia in a nutshell. Lancet. 2012 Feb 25;379(9817):776. doi: 10.1016/S0140-6736(11)61643-7. No abstract available. PMID 22364760
- Arnold J, Ouwehand WH, Smith GA, Cohen H. A young woman with petechiae. Lancet. 1998 Aug 22;352(9128):618. doi: 10.1016/s0140-6736(98)05194-0. No abstract available. PMID 9746024
- LAVY R. THROMBOCYTOPENIC PURPURA DUE TO LUPINUS TERMIS BEAN. J Allergy. 1964 Sep-Oct;35:386-9. doi: 10.1016/0021-8707(64)90065-6. No abstract available. PMID 14216353
- Kam T, Alexander M. Drug-induced immune thrombocytopenia. J Pharm Pract. 2014 Oct;27(5):430-9. doi: 10.1177/0897190014546099. Epub 2014 Aug 17. PMID 25134884
Identifiers
NCT: NCT07182760 · S.I.TH